新型4-喹诺酮化合物Ro 23-6240的体外活性

In vitro activity of the new 4-quinolone compound Ro 23-6240.

作者信息

Clarke A M, Zemcov S J

出版信息

Eur J Clin Microbiol. 1987 Apr;6(2):161-4. doi: 10.1007/BF02018199.

DOI:10.1007/BF02018199

Abstract

The in vitro activity of the new 4-quinolone Ro 23-6240 was compared with that of pefloxacin, ciprofloxacin, norfloxacin, nalidixic acid and gentamicin against a total of 397 recent clinical isolates. An agar dilution procedure was used to determine MICs and two inocula (10(4) and 10(6) CFU) were used throughout. Ro 23-6240 inhibited most species of the Enterobacteriaceae, Haemophilus influenzae and Staphylococcus aureus (including methicillin-resistant strains) at less than or equal to 1 mg/l. Pseudomonas aeruginosa was somewhat more resistant (MIC 90 4 mg/l) and the Bacteroides fragilis group were considerably more resistant (MIC 90 32 mg/l). Overall Ro 23-6240 was as active as pefloxacin but was two- to eight-fold less active than ciprofloxacin against most species tested.

摘要

将新型4-喹诺酮Ro 23-6240的体外活性与培氟沙星、环丙沙星、诺氟沙星、萘啶酸和庆大霉素针对总共397株近期临床分离株的活性进行了比较。采用琼脂稀释法测定最低抑菌浓度（MIC），并始终使用两种接种量（10⁴和10⁶CFU）。Ro 23-6240对大多数肠杆菌科细菌、流感嗜血杆菌和金黄色葡萄球菌（包括耐甲氧西林菌株）的抑制浓度小于或等于1mg/l。铜绿假单胞菌的耐药性略高（MIC90为4mg/l），脆弱拟杆菌组的耐药性则高得多（MIC90为32mg/l）。总体而言，Ro 23-6240的活性与培氟沙星相当，但对大多数测试菌株的活性比环丙沙星低两至八倍。